Docetaxel in the treatment of esophageal cancer

Seminars in Oncology

Volumn 32, Issue SUPPL. 4, 2005, Pages 39-51

  Rigas, James R ^a,b   Dragnev, Konstantin H ^a   Bubis, Jeffrey A ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; MITOMYCIN; PACLITAXEL;

ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ASTHENIA; BRAIN DISEASE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CONSTIPATION; DIARRHEA; DRUG CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MONITORING; DRUG SAFETY; DYSPHAGIA; EDEMA; ESOPHAGITIS; ESOPHAGUS CARCINOMA; ESOPHAGUS METASTASIS; ESOPHAGUS RESECTION; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; LEUKOPENIA; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; STOMATITIS; THROMBOCYTOPENIA; UREMIA; VOMITING;

EID: 19444371684     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.04.005     Document Type: Article

References (63)

1. N.E. Day, C. Varghese Oesophageal cancer Cancer Surv 19-20 1994 43 54
2. R.T. Greenlee, T. Murray, S. Bolden Cancer statistics, 2000 CA Cancer J Clin 50 2000 7 33
3. A.P. Vizcaino, V. Moreno, R. Lambert Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995 Int J Cancer 99 2002 860 868
4. S.G. Swisher, J.A. Ajani, R.K. Komaki Neoplasms of the esophagus D.W. Kufe R.E. Pollock R.R. Weichselbaum Cancer Medicine (ed 6) 2003 Inc London, BC Decker 1499 1514
5. P.C. Enzinger, D.H. Ilson, D.P. Kelsen Chemotherapy in esophageal cancer Semin Oncol 26 suppl 15 1999 12 20
6. National Comprehensive Cancer Network: Esophageal Cancer Clinical Practice Guidelines in Oncology, Version 1. 2004 2004 Available at: www.nccn.org (accessed July 13)
7. M.D. Gammon, J.B. Schoenberg, H. Ahsan Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia J Natl Cancer Inst 89 1997 1277 1284
8. W.J. Blot Alcohol and cancer Cancer Res 52 1992 2119s 2123s
9. L.M. Brown, C.A. Swanson, G. Gridley Adenocarcinoma of the esophagus Role of obesity and diet J Natl Cancer Inst 87 1995 104 109
10. M.A.M. Rogers, T.L. Vaughan, S. Davis Consumption of nitrate, nitrite, and nitrosodimethylamine and the risk of upper aerodigestive tract cancer Cancer Epidemiol Biomarkers Prev 4 1995 29 36
11. W.-H. Chow, W.J. Blot, T.L. Vaughan Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia J Natl Cancer Inst 90 1998 150 155
12. S.J. Spechler Barrett's esophagus and esophageal adenocarcinoma Pathogenesis, diagnosis, and therapy Med Clin North Am 86 2002 1423 1445
13. I.B. Paz, J.J. Hwang, J.L. Marshall Esophageal cancer R. Pazdur L.R. Coia W.J. Hoskins L.D. Wagman Cancer Management A Multidisciplinary Approach (ed 8) 2004 PRR, Inc Melville, NY 239 258
14. A. Jemal, T. Murray, A. Samuels Cancer statistics, 2003 CA Cancer J Clin 53 2003 5 26
15. A.B. Jani, P.P. Connell, V.J. Vesich Analysis of the role of adjuvant chemotherapy for invasive carcinoma of the esophagus Am J Clin Oncol 23 2000 554 558
16. I.G. Kaklamanos, G.R. Walker, K. Ferry Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction A meta-analysis of randomized clinical trials Ann Surg Oncol 10 2003 754 761
17. J.I. Geh The use of chemoradiotherapy in oesophageal cancer Eur J Cancer 38 2002 300 313
18. D. Kelsen Treatment of advanced esophageal cancer Cancer 50 1982 2576 2581
19. L. Leichman, B.T. Berry Experience with cisplatin in treatment regimens for esophageal cancer Semin Oncol 18 1991 64 72
20. J.A. Ajani Contributions of chemotherapy in the treatment of carcinoma of the esophagus Results and commentary Semin Oncol 21 1994 474 482
21. J.A. Ajani, D.H. Ilson, K. Daugherty Paclitaxel in the treatment of carcinoma of the esophagus Semin Oncol 22 1995 35 40
22. E.I. Heath, S. Urba, J. Marshall Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus Invest New Drugs 20 2002 95 99
23. T. Taguchi A late phase II study of docetaxel in patients with gastric cancer Proc Am Soc Clin Oncol 16 1997 263a (abstr 934)
24. A.I. Einzig, D. Neuberg, S.C. Remick Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy The Eastern Cooperative Oncology Group (ECOG) Results of Protocol E1293 Med Oncol 13 1996 87 93
25. D. Mavroudis, C. Kourousis, N. Androulakis Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF). A phase II trial Am J Clin Oncol 23 2000 341 344
26. A. Sulkes, J. Smyth, C. Sessa Docetaxel (Taxotere) in advanced gastric cancer Results of a phase II clinical trial Br J Cancer 70 1994 380 383
27. K. Muro, T. Hamaguchi, A. Ohtsu A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer Ann Oncol 15 2004 955 959
28. P. Bhargava, J.L. Marshall, K. Fried Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer Cancer Chemother Pharmacol 48 2001 95 103
29. G.S. Long, M.F. Earle, T.L. Evans Phase I study of gemcitabine, docetaxel and carboplatin triple drug combination (GDC), with & without filgrastim (G-CSF) support, in patients with advanced non-hematological malignancies Proc Am Soc Clin Oncol 19 2000 227a (abstr 890)
30. M.E. Poole, M.A. Churchel, S.A. Bernard Phase I study of gemcitabine and docetaxel for locally advanced and/or metastatic cancer of the head and neck, non-colorectal gastrointestinal cancer, hepatoma, and soft tissue sarcoma Proc Am Soc Clin Oncol 19 2000 222a (abstr 866)
31. J. Rigas, M.L. Rothenberg, T.H. Davis Phase I clinical and pharmacokinetic study of docetaxel in combination with two gemcitabine infusion schedules Proc Am Soc Clin Oncol 18 1999 226a (abstr 870)
32. D.P. Ryan, T.J. Lynch, M.L. Grossbard A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors Cancer 88 2000 180 185
33. C.H. Spiridonidis, L.R. Laufman, J. Jones Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies J Clin Oncol 16 1998 3866 3873
34. E. Van Den Neste, D. de Valeriola, J. Kerger A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors Clin Cancer Res 6 2000 64 71
35. M.F. Mulcahy, P.J. Loehrer, N.J. Meropol Phase I study of docetaxel, cisplatin, 5-FU and leucovorin Proc Am Soc Clin Oncol 20 2001 171a (abstr 682)
36. G. Marx, C. Lewis, K. Hall Phase I study of docetaxel plus ifosfamide in patients with advanced cancer Br J Cancer 87 2002 846 849
37. S.L. Zaknoen, J. Crawford, F. Shepherd Phase I study of oral lonafarnib plus docetaxel as second-line treatment for advanced solid tumors Proc Am Soc Clin Oncol 21 2002 81b (abstr 2136)
38. A.M. Mauer, G.A. Masters, D.J. Haraf Phase I study of docetaxel with concomitant thoracic radiation therapy J Clin Oncol 16 1998 159 164
39. H.G. Chun, C.A. Puccio, A. Mittelman Weekly docetaxel and continuous infusion (CI) 5-fluorouracil (5-FU) in elderly patients (pts) with cancer of the stomach and distal esophagus Proc Am Soc Clin Oncol 20 2001 162a (abstr)
40. M. Tria Tirona, A. Jatoi, S.S. Cha A phase II trial of CPT-11 and docetaxel in patients with metastatic esophageal cancer Preliminary toxicity data from the North Central Cancer Treatment Group Proc Am Soc Clin Oncol 21 2002 152a (abstr 605)
41. F. Lordick, H. Bernhard, C. von Schilling Phase II study of CPT-11 plus docetaxel in esophageal cancer patients previously treated with cisplatin Proc Am Soc Clin Oncol 21 2002 126b (abstr 2317)
42. M. Margelí, A. Font, A. Arellano A phase II study of weekly docetaxel and concurrent radiation in patients (pts) with unresectable esophageal cancer Eur J Cancer 37 suppl 6 2001 S315 (abstr 1166)
43. M. Suntharalingam, C.M. DeYoung, M.J. Edelman Concomitant boost RT as part of an induction regimen followed by surgery and adjuvant docetaxel for locally advanced esophageal cancer Proc Am Soc Clin Oncol 21 2002 167a (abstr 667)
44. A.M. Mauer, D.C. Haraf, M.K. Ferguson Docetaxel-based combined modality therapy for locally advanced carcinoma of the esophagus and gastric cardia Proc Am Soc Clin Oncol 19 2000 246a (abstr 954)
45. A. Font, P. Garcia-Alfonso, A. Arellano Preoperative combined multimodal therapy with docetaxel plus 5-fluorouracil and concurrent hyperfractionated radiotherapy for locally advanced esophageal cancer Proc Am Soc Clin Oncol 21 2002 128b (abstr 2326)
46. I. Williams, K.H. Dragnev, S. Gordon A novel tri-modality approach for the treatment of stage II-III cancer of the esophagus 2003 From proceedings of the 14th International Congress on Anti-Cancer Treatment, Paris, France, (abstr 204)
47. J.A. Bubis, I. Williams, K.H. Dragnev Docetaxel (DTX) and carboplatin (CP) followed by a dose-ranging study of oral capecitabine, weekly DTX, concomitant radiotherapy and surgery for the treatment of patients with stage II-III carcinoma of the esophagus Proc Am Soc Clin Oncol 23 2004 324 (abstr 4049)
48. I. Ringel, S.B. Horwitz Studies with RP 56976 (Taxotere) A semisynthetic analogue of Taxol J Natl Cancer Inst 83 1991 288 291
49. J.F. Díaz, J.M. Andreu Assembly of purified GDP-tubulin into microtubules induced by Taxol and taxotere Reversibility, ligand stoichiometry, and competition Biochemistry 32 1993 2747 2755
50. P.B. Schiff, S.B. Horwitz Taxol stabilized microtubules in mouse fibroblast cells Proc Natl Acad Sci U S A 77 1980 1561 1565
51. J.E. Cortes, R. Pazdur Docetaxel J Clin Oncol 13 1995 2643 2655
52. Taxotere [package insert]. Bridgewater, NJ, Aventis Pharmaceuticals, Inc, 2004
53. K.A. Mason, N.R. Hunter, M. Milas Docetaxel enhances tumor radioresponse in vivo Clin Cancer Res 3 1997 2431 2438
54. M. Tanaka, T. Obata, T. Sasaki Evaluation of antitumour effects of docetaxel (Taxotere) on human gastric cancers in vitro and in vivo Eur J Cancer 32A 1996 226 230
55. P. Nadella, C. Shapiro, G.A. Otterson Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies J Clin Oncol 20 2002 2616 2623
56. A.M. Storniolo, S.R.B. Allerheiligen, H.L. Pearce Preclinical, pharmacologic, and phase I studies of gemcitabine Semin Oncol 24 suppl 7 1997 S7-2 S7-7
57. A.A. Adjei, C.E. Klein, H. Kastissios Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors Preliminary evidence of clinical activity J Clin Oncol 18 2000 1116 1123
58. M. Al-Sarraf, K. Martz, A. Herskovic Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer An intergroup study J Clin Oncol 15 1997 277 284
59. A. Herskovic, K. Martz, M. Al-Sarraf Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus N Engl J Med 326 1992 1593 1598
60. W.O. Rebecca, M.A. Richard Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus Cochrane Database Syst Rev 1 2003 CD002092
61. T.N. Walsh, N. Noonan, D. Hollywood A comparison of multimodal therapy and surgery for esophageal adenocarcinoma N Engl J Med 335 1996 462 467
62. J. Rigas A novel tri-modality approach for the treatment of stage II-III esophageal cancer. Clinical highlights; Oncology report and commentary from the fourteenth international congress on Anti-Cancer Treatment 2003 NorthStar Clinical Communications
63. Rigas J: Phase I study of neoadjuvant docetaxel and carboplatin followed by capecitabine and docetaxel with concurrent external beam radiotherapy in patients with stage II or III carcinoma of the esophagus or gastroesophageal junction. Protocol DMS-9939, NCI-G01-1931, 2001. Available at: http://www.clinicaltrials.gov/show/NCT00014417